Analysis of circulating genetically abnormal cells in lung cancer patients

基于合适的分子生物标志物的个性化药物有望改善肺癌患者的预后。对于晚期肺癌患者，利用循环肿瘤细胞或无细胞DNA(即液体活检)进行生物标记物分析是快速、简单和非侵入性的。我建立了一个从有限数量的样本中快速、同时检测多个基因改变的系统，以有效地选择治疗人群。

Personalized medicine based on appropriate molecular biomarkers is hoped to improve prognoses of lung cancer patients. Biomarker analyses with circulating tumor cells or cell-free DNA (i.e., liquid biopsy) are quick, simple and non-invasive for advanced lung cancer patients. I established a rapidly and simultaneously detecting system of multiple genetic alterations from limited amounts of samples for efficiently selecting therapeutic populations.